Sphera Funds Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Sphera Funds Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-47,309	Closed	-$7.64M	–	162
2021 Q2	$7.64M	Buy	47,309 +17,530	+59%	+$2.81M	0.52%	56
2021 Q1	$5.1M	Hold	29,779	–	–	0.39%	70
2020 Q4	$6.54M	Sell	29,779 -3,221	-10%	-$696K	0.58%	54
2020 Q3	$5.48M	Sell	33,000 -39,000	-54%	-$5.34M	0.54%	55
2020 Q2	$8.22M	Buy	+72,000	New	+$6.98M	0.77%	34
2018 Q4	–	Sell	-112,908	Closed	-$5.32M	–	129
2018 Q3	$5.32M	Buy	112,908 +98,573	+688%	+$5.49M	0.61%	43
2018 Q2	$707K	Buy	+14,335	New	+$541K	0.1%	93
2017 Q1	–	Sell	-80,528	Closed	-$383K	–	127
2016 Q4	$383K	Sell	80,528 -69,472	-46%	-$378K	0.1%	93
2016 Q3	$992K	Hold	150,000	–	–	0.16%	95
2016 Q2	$819K	Buy	+150,000	New	+$2.39M	0.21%	82
2015 Q4	–	Sell	-80,000	Closed	-$2.75M	–	139
2015 Q3	$2.75M	Sell	80,000 -15,000	-16%	-$453K	0.35%	69
2015 Q2	$2.99M	Sell	95,000 -5,000	-5%	-$147K	0.29%	89
2015 Q1	$2.93M	Buy	+100,000	New	+$2.35M	0.31%	81

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Sphera Funds Management's MRTX Position: Q3 2021 in Review

Sphera Funds Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q3 2021, closing a stake of 47,309 shares — an estimated $7.64M sold.

Sphera Funds Management first reported a position in MRTX in Q1 2015 and held it in 13 quarters. The position peaked at $8.22M in Q2 2020. 238 funds tracked by Wall St. Rank hold MRTX as of Q3 2021.

Sphera Funds Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
Sphera Funds Management sold 47,309 Mirati Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $7.64M.
Sphera Funds Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 13 quarters.
Sphera Funds Management's Mirati Therapeutics, Inc. Common Stock position peaked at $8.22M in Q2 2020.
238 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Sphera Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.